Compare GSK plc (GSK) vs Goodyear Tire & Rubber Co (GT) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

GT trades at $7.18, up 7.81% today, with a bullish technical signal and moving average alignment. The stock shows attractive valuation ratios (P/E 4.69, P/B 0.64) but faces profitability challenges, with a net income margin of -11.64% in 2025. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering. Q1 2026 earnings beat estimates, yet revenue trends are declining.

Outlook: Deep value metrics and analyst consensus target of $8.75 suggest upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Investors should weigh low valuation against operational headwinds and macroeconomic sensitivity.